Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940218 | 1.00 | MAPK1 (0.50) | MAPK1RORCGPR119USP30JAK2 | |
| SCHEMBL19745334 | 1.00 | MAPK1 (0.50) | MAPK1RORCGPR119USP30JAK2 | |
| SCHEMBL28225677 | 1.00 | MAPK1 (0.50) | MAPK1RORCGPR119USP30JAK2 | |
| Hydrochloric Acid SCHEMBL28503227 | 0.99 | MAPK1 (0.49) | MAPK1RORCGPR119USP30JAK2 | |
| SCHEMBL26102356 | 0.88 | GPR119 (0.49) | MAPK1RORCGPR119 | |
| SCHEMBL16026535 | 0.88 | ESR2 (0.44) | MAPK1RORCGPR119USP30KDM4E | |
| SCHEMBL6017253 | 0.88 | GPR119 (0.49) | MAPK1RORCGPR119 | |
| SCHEMBL6028557 | 0.88 | GPR119 (0.56) | MAPK1GPR119KDM4EPKMHPGDS | |
| SCHEMBL38661093 | 0.87 | MAPK1 (0.45) | MAPK1GPR119USP30 | |
| SCHEMBL3694373 | 0.87 | RORC (0.44) | MAPK1RORCGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE5A, PDE7A | MAPK1 2232/4885RORC 2792/4885GPR119 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.